IRIS UniCatt

Laurenti, Luca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.575
AS - Asia 10.571
EU - Europa 9.955
SA - Sud America 2.362
Continente sconosciuto - Info sul continente non disponibili 579
AF - Africa 310
OC - Oceania 189
Totale 41.541
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.030
SG - Singapore 4.714
CN - Cina 2.583
DE - Germania 2.473
BR - Brasile 1.919
IT - Italia 1.815
SE - Svezia 1.663
VN - Vietnam 933
FR - Francia 891
UA - Ucraina 673
GB - Regno Unito 577
IE - Irlanda 521
IN - India 467
ID - Indonesia 357
FI - Finlandia 328
CA - Canada 283
BD - Bangladesh 265
RU - Federazione Russa 260
JP - Giappone 250
HK - Hong Kong 187
AR - Argentina 181
TR - Turchia 160
AU - Australia 159
PL - Polonia 141
MX - Messico 130
NL - Olanda 110
IQ - Iraq 105
KR - Corea 87
ZA - Sudafrica 77
ES - Italia 73
AT - Austria 69
SA - Arabia Saudita 60
EC - Ecuador 53
CO - Colombia 50
PK - Pakistan 48
BE - Belgio 44
CI - Costa d'Avorio 43
MA - Marocco 43
UZ - Uzbekistan 41
VE - Venezuela 40
EG - Egitto 38
CH - Svizzera 35
CL - Cile 33
PY - Paraguay 32
CZ - Repubblica Ceca 31
NZ - Nuova Zelanda 30
JO - Giordania 29
HU - Ungheria 28
RO - Romania 28
IR - Iran 27
KE - Kenya 27
IL - Israele 26
PH - Filippine 25
JM - Giamaica 24
NP - Nepal 24
DZ - Algeria 22
LT - Lituania 21
AE - Emirati Arabi Uniti 20
BG - Bulgaria 20
PE - Perù 20
TH - Thailandia 20
GR - Grecia 19
MY - Malesia 19
CR - Costa Rica 18
BO - Bolivia 16
LB - Libano 16
PT - Portogallo 16
AZ - Azerbaigian 15
TT - Trinidad e Tobago 14
ET - Etiopia 13
UY - Uruguay 13
HN - Honduras 12
NO - Norvegia 12
OM - Oman 12
DO - Repubblica Dominicana 11
KZ - Kazakistan 11
RS - Serbia 11
SK - Slovacchia (Repubblica Slovacca) 11
AL - Albania 10
HR - Croazia 10
LK - Sri Lanka 10
BA - Bosnia-Erzegovina 9
MD - Moldavia 9
NI - Nicaragua 8
PR - Porto Rico 8
SI - Slovenia 8
BB - Barbados 7
SN - Senegal 7
TN - Tunisia 7
TW - Taiwan 7
DK - Danimarca 6
EU - Europa 6
KW - Kuwait 6
LV - Lettonia 6
PA - Panama 6
QA - Qatar 6
XK - ???statistics.table.value.countryCode.XK??? 6
AM - Armenia 5
AO - Angola 5
BY - Bielorussia 5
Totale 40.859
Salva come PNG Salva come JPEG
Città #
Singapore 2.379
Ashburn 1.522
Chandler 1.299
San Jose 1.249
Beijing 547
Dublin 500
Jacksonville 396
Los Angeles 375
San Mateo 338
New York 330
Jakarta 313
Lauterbourg 304
Ho Chi Minh City 298
Dearborn 286
Nanjing 281
Rome 274
Milan 270
Wilmington 260
Hanoi 246
Hefei 244
Tokyo 219
Dallas 208
Council Bluffs 194
Ann Arbor 192
Boston 187
Munich 178
Hyderabad 177
Florence 175
Chicago 174
Hong Kong 169
Frankfurt am Main 166
Cattolica 153
São Paulo 151
Houston 148
Woodbridge 141
Buffalo 136
Redwood City 136
Moscow 133
Seattle 127
Atlanta 124
Lawrence 123
Princeton 122
Nürnberg 120
Nanchang 116
Redmond 108
Helsinki 105
Marseille 104
Santa Clara 104
Boardman 97
Tukwila 96
Fairfield 94
Orem 93
Warsaw 91
Lancaster 86
Izmir 80
Brooklyn 79
Kunming 78
Seoul 75
Phoenix 74
Bremen 72
Rio de Janeiro 69
San Francisco 69
London 65
The Dalles 63
Kent 60
Tianjin 60
Mountain View 55
Paris 55
Washington 54
Shanghai 52
Shenyang 51
Toronto 51
Guangzhou 50
Montreal 49
Lappeenranta 48
Philadelphia 48
Denver 47
Norwalk 45
Belo Horizonte 44
Nuremberg 44
Abidjan 43
Zhengzhou 43
Stockholm 42
Mexico City 41
Cambridge 39
Da Nang 39
Düsseldorf 39
Naples 39
Brussels 38
Haiphong 38
Porto Alegre 38
Pune 38
Chennai 37
Tashkent 37
Detroit 36
Sydney 36
Turku 36
Vienna 36
Baghdad 35
Hangzhou 35
Totale 18.760
Salva come PNG Salva come JPEG
Nome #
VITAMIN B12 DEFICIENCY: CORRELATION BETWEEN MTHFR POLYMORPHISMS AND CLINICAL AND LABORATORY FINDINGS 3.869
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation 661
HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST LINE TREATMENT FOR HIGH-RISK DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB ERA: AN INTENTION TO TREAT-ANALYSIS 437
Reliability of leukostasis grading score to identify patients with high-risk hyperleukocytosis 386
Factors associated with mortality in bacteremic patients with hematologic malignancies. 380
Elevated lactate dehydrogenase has prognostic relevance in treatment-naïve patients affected by chronic lymphocytic leukemia with trisomy 12 333
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia 301
Implications of Genetic, Biological and Clinical Parameters in Patients With Richter Syndrome: A Monocentric Experience 268
First-line treatment of Waldenström's macroglobulinemia in Italy: A multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies 251
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia 248
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 245
Prospective study of hepatitis B virus reactivation in patients with hematological malignancies 240
CAR-T Cells in Chronic Lymphocytic Leukemia 235
Correlation between paraproteinaemia and viral reactivation after allo-SCT 229
Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation 227
Low-dose valganciclovir as preemptive therapy for cytomegalovirus infection occurring in allogeneic stem cell transplant recipients 224
Factors associated with mortality in bacteremic patients with hematologic malignancies. 220
Severe veno-occlusive disease after autologous peripheral blood stem cell transplantation for high-grade non-Hodgkin lymphoma: report of a successfully managed case and a literature review of veno-occlusive disease. 219
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes 213
Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome 211
Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: safety and efficacy evaluation 203
Evaluation of intraorbital injection of rituximab for treatment of primary ocular adnexal lymphoma. A pilot study. 199
Peripherally inserted central catheters (PICCs) in the management of oncohematological patients submitted to autologous stem cell transplantation 181
Low incidence of secondary neoplasia after autotransplantation for lymphoproliferative disease: the role of pre-transplant therapy 180
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 180
Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia 177
Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation 174
New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia 172
Role of (18)F-FDG PET-CT for evaluating the response to reduced-intensity conditioning allogeneic transplant in heavily pre-treated patients with chronic lymphocytic leukemia: preliminary results in nine patients 171
Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia 171
Work related acute leukemia and mucor mycosis in a boat-builder 170
The use of low-dose alemtuzumab in pretreated B-cell chronic lymphocytic leukemia. Leukemia. 168
All-trans retinoic acid in association with low dose cytosine arabinoside in the treatment of acute myeoid leukemia in elderly patients 168
Chronic lymphocytic leukemia with eyelid involvement responding to alemtuzumab. 167
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 167
Immune recovery after low-dose Campath therapy in a group of pretreated patients affected by B-cell chronic lymphocytic leukemia [9] 165
Hyperleukocytosis and leukostasis: management of a medical emergency 165
Hyperleukocytosis and leukostasis: management of a medical emergency 164
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 164
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation 163
EXTREME THROMBOCYTOSIS IN CHRONIC MYELOID LEUKEMIA IN THE ERA OF TYROSINE KINASE INHIBITORS 163
Role of 18F-FDG PET-CT for evaluating the response to reduced-intensity conditioning allogeneic transplant in heavily pre-treated patients with chronic lymphocytic leukemia: preliminary results in nine patients. 162
Clinical Outcomes in Double-Exposed Chronic Lymphocytic Leukemia Patients in Italy 162
The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia 161
Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: Safety and efficacy evaluation. 161
Role of microRNAs in Chronic Lymphocytic Leukemia 160
Neurologic improvement after peripheral blood stem cell transplantation in poems 160
TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients 158
Clinical reversible myelopathy in T-cell lymphoblastic lymphoma treated with nelarabine and radiotherapy: report of a case and review of literature of an increasing complication 157
Clinical reversible myelopathy in T-cell lymphoblastic lymphoma treated with nelarabine and radiotherapy: report of a case and review of literature of an increasing complication. 157
Clinical and pathological heterogeneity in a series of 31 patients with IgM-related neuropathy 156
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 156
Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration 155
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 154
Usefulness of F-18 FDG PET/CT in the follow-up of POEMS syndrome after autologous peripheral blood stem cell transplantation 153
revalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience. 153
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 153
The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue 152
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 152
Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia 151
Light chain deposition in peripheral nerve as a cause of mononeuritis multiplex in Waldenström's macroglobulinaemia. 150
Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. 149
Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study 148
H1N1 Influenza among Hematological Patients: Monocentric Influenza Cases from 2011 to 2016 148
Evaluation of intraorbital injection of rituximab for treatment of primary ocular adnexal lymphoma: a pilot study 148
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification 146
Granulocyte transfusions as adjunctive treatment of invasive fungal diseases in neutropenic patients 144
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T 142
Guillain-Barre' syndrome following Varicella zoster reactivation in Chronic Lymphocytic Leukemia treated with fludarabine 142
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 142
Mycosis fungoides as a cause of severe obstructive sleep apnea 141
Invasive fungal infections in chronic lymphoproliferative disorders: A monocentric retrospective study 141
The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience 140
Chlorambucil plus Rituximab as Front-Line Therapy in Elderly/Unfit Patients Affected by B-Cell Chronic Lymphocytic Leukemia: Results of a Single-Centre Experience 140
Peripherally inserted central catheters (PICCs) in the management of oncohematological patients submitted to autologous stem cell transplantation 139
Acute graft versus host disease 1976-2020: reduced incidence and predictive factors 138
Non-tunnelled central venous catheters in adult stem cell transplantation recipients: an effective option 138
Long-term follow up of frontline therapy with fludarabine and cyclophosphamide in chronic lymphocytic leukemia: impact of biological parameters on clinical outcome 138
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. 136
High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia 135
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome 135
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib 134
Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia 133
Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics 133
NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia 131
Allogeneic hematopoietic stem cell transplantation in therapy-related myeloid neoplasms (t-MN) of the adult: Monocentric observational study and review of the literature 131
Unselected donor-derived hematopoietic stem cells boost for Chimeric Antigen Receptor T-cell associated hematotoxicity 130
Chronic Lymphocytic Leukaemia: Census of Patients Treated in Italian Haematology Units 130
Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia. 130
Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections. 130
Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome 130
Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease 128
Reduced-intensity conditioning allogeneic transplant in heavily pre-treated chronic lymphocytic leukaemia patients: a single centre experience 128
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma 127
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 127
The Syk kinase as a therapeutic target in leukemia and lymphoma 126
What Does Atypical Chronic Lymphocytic Leukemia Really Mean? A Retrospective Morphological and Immunophenotypic Study 125
Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease 124
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia 124
Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study 124
Totale 21.427
Salva come PNG Salva come JPEG
Categoria #
all - tutte 171.587
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 171.587
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.960 0 125 122 148 158 62 36 304 96 119 412 378
2022/20234.158 593 587 327 507 310 518 186 295 470 81 210 74
2023/20243.915 123 692 197 767 218 476 187 110 125 231 376 413
2024/20256.148 370 266 490 236 458 195 182 287 795 682 1.275 912
2025/202614.489 2.127 489 978 1.553 2.177 800 2.185 810 978 1.048 708 636
2026/20272.918 705 2.213 0 0 0 0 0 0 0 0 0 0
Totale 41.541